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Abstract
Background:Venous thromboembolism (VTE) is a serious, sometimes life-threatening complication that can occur following spine
surgery. The incidence of VTE, and the optimal type and timing of thromboprophylaxis for this complication in elective spine surgery is
a matter of debate.
Objective: To perform a systematic review with the aim of clarifying the efficacy and adverse effects of mechanical and chemical
prophylaxis for preventing thromboembolic complications in elective spine surgery for conditions other than traumaandmalignant disease.
Methods/design: A search strategy of related articles up to March 2018 was designed and executed in Medline and Embase.
Patients: adolescents (>10 years) and adults undergoing elective surgery for spinal deformity or degenerative disease (from C1 to
S1). Intervention: Perioperative mechanical and chemical thromboprophylaxis. Studies could be randomized controlled trials or
observational studies that reported data on any relevant clinical outcomes.
Results: In total, 2451 uniquecitations were identified and 35 studies were ultimately included in the systematic review. The overall
mean incidence of complications was 3.7% for deep venous thrombosis, 0.0% for pulmonary embolism, and 3.7% for bleeding in
chemoprophylaxis group; 2.9% for deep venous thrombosis, 0.4% for pulmonary embolism and 0.0% for bleeding in
mechanoprophylaxis; and 0.7% for deep venous thrombosis, 0.1% for pulmonary embolism and 0.2% for bleeding in mixed
prophylaxis group with no specific data on these rates for the type of patient and type and location of surgery. None of the articles
retrieved provided information on the adolescent population.
Discussion and Conclusions: The poor design and high variability among the studies regarding characteristics of study
population, details of interventions, and definitions of outcomes, determines a low quality of the available evidence and limits the
interpretation of the results. We were unable to identify a clear advantage of one type of thromboprophylaxis over the other, although
there was an increased risk of bleeding with chemoprophylaxis, which could favor the use of mechanoprophylaxis in this scenario.
Abbreviations: ACCP= American College of Chest Physicians, CS=Compression Stockings, DVT=Deep Venous Thrombosis,
EDH = Epidural Hematoma, LDUH = Low-Dose Unfractionated Heparin, LMWH = Low Molecular Weight Heparine, NASS = North
American Spine Society, PE = Pulmonary Embolism, RCTs = Randomized Controlled Trials, SPC = Sequential Pneumatic
Compression Devices, VTE = Venous Thromboembolism.
Keywords: chemoprophylaxis, deep vein thrombosis, epidural hematoma, mechanoprophylaxis, pulmonary embolism, spine
surgery, thromboprophylaxisEditor: Johannes Mayr.
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 There is no clinically difference between chemoprophy-
laxis and mechanoprophylaxis regarding VTE or PE
incidence.
 The appropriate time for the start of postoperative
anticoagulation has not yet been determined.
 The use of chemoprophylaxis is related to the occurrence
of bleeding complications.
 There is a lack of information in the adolescent
population (under 18 years of age) on the incidence of
VTE or PE or the effectiveness of thromboprophylaxis.
 This systematic review confirms the low quality of
research in this field.1. Introduction
Venous thromboembolism (VTE), including deep venous
thrombosis (DVT), and pulmonary embolism (PE), is a serious
and potentially fatal complication that can occur in the
postoperative period following spine surgery.[1] DVT and PE
have both been extensively studied in several types of orthopedic
and trauma surgeries. However, data on the incidence and impact
of VTE in spine surgery is more limited, and currently, there is no
clear consensus onwhat constitutes optimal thromboprophylaxis
in these procedures.[2] This is particularly true for elective spine
surgery performed for conditions other than trauma or a
malignant disease.[1,3,4]
The documented incidence ofVTE in spine surgery varieswidely
from 0.3% to 31%, depending on the population studied and the
methods used to detect this complication.[5] It is likely that this
considerable divergence is the result of including patients with
different conditions (e.g., degenerative spinal disease, deformity,
traumatic injury, and tumors) affecting different parts of the spine
and treated with heterogeneous surgical techniques.[6,7]
The risk–benefit relationship of thromboprophylaxis in this
setting should also be considered. When deciding on the type and
timing of thromboprophylaxis, the risk of postoperative bleeding
and epidural hematoma (EDH)must be carefully weighed against
the benefits of averting thromboembolic complications, and this
may be a complex task in clinical practice.[7–11]
Among the systematic reviews on the indications and risks of
thromboprophylaxis in general spine surgery[5,12–14] we highlight
the study by Glotzbecker et al,[5] which reported a DVT rate
influenced by the method of thromboprophylaxis—no prophy-
laxis, 2.7%; compression stockings (CS), 2.7%; sequential
pneumatic compression devices (SPC), 4.6%; SPC + CS, 1.3%;
chemical prophylaxis 0.6%; and vena cava filter with/without
another prophylaxis method, 12%—and by the diagnostic
method used, with a range of 1% to 12.3%. The authors of
this review concluded that the DVT rate was quite low in elective
spine surgery and that mechanical prophylaxis could be the
method of choice in most cases. Routine chemoprophylaxis was
not recommended because of insufficient evidence, except in
patients with cord lesions and those undergoing high-risk spinal
surgery (simultaneous dual approach or malignant disease). The
systematic review by Cheng et al[12] was mainly focused on the
risk of anticoagulant administration in general spine surgery
(mechanical thromboprophylaxis was not assessed). The studies2
included were grouped according to the type of spine disease:
degenerative, deformity, trauma, infection, and malignant
disease. There was a higher risk of DVT in spine surgery for
non-traumatic causes (6%, range 0–19%) and for deformity
(5.3%, range 2–14%), and a lower risk in surgery for
degenerative conditions (2.3%, range 0–9%). The overall risk
of DVT in elective surgery without pharmacological prophylaxis
was 1% to 2%. The risk of major bleeding ranged from 0% to
4.3% with use of a variety of anticoagulant agents. This study
was unable to establish the safest time point to initiate
coagulation in the postoperative period, as none of the studies
had defined this objective, nor the most appropriate treatment
option. Some of the conclusions were derived from a small
number of studies; hence, the authors considered that the quality
of the evidence for the associated risk of DVT in the different
types of spine surgery was of low or very low level, particularly in
the case of elective surgery. Despite these limitations, the
conclusions suggested that patients undergoing elective spine
surgery could undergo the procedure without the use of
pharmacologic prophylaxis. A more recent systematic review
carried out by Oliveira et al[13] reported average overall rates of
3.55% and 1.04% for DVT and PE, respectively, in all types of
spine surgery. The authors stated that it was not possible to
indicate a standard thromboprophylaxis for spine surgery, as can
be done for hip and knee surgeries, because of the heterogeneous
nature of the studies. Additionally, chemoprophylaxis may not be
safe due to the possibility of bleeding complications. Therefore, it
falls to the spinal surgeon to analyze the risk of DVT/PE
individually for each specific case. The authors emphasized the
importance of symptomatic EDH, which often shows rapidly
progressing neurological deterioration and can be associated
with coagulopathy induced by the administration of anti-
coagulants. Around 4% of patients who received systemic
LMWH prophylaxis developed bleeding complications, com-
pared with the 0.5% to 2.5% of patients who developed DVT
following spinal surgery, making this a substantial disincentive
for chemoprophylaxis in these procedures, although this was not
specifically described in the review.[15,16]
On the other hand, the North American Spine Society (NASS)
and American College of Chest Physicians (ACCP) have
published guideline for VTE prophylaxis in non-traumatic,
non-neoplastic elective spine surgery.[17,18] Nevertheless, all these
recommendations are based on a small number of studies
including a limited number of patients and showing significant
methodological defects.
Since the publication of these guidelines, new data on the
outcomes of different types of thromboprophylaxis in spinal
surgery have been published. As there is considerable uncertainty
regarding the optimal thromboprophylactic regimen to use in
elective spine surgery, we carried out a systematic review on this
topic. We aimed to evaluate the efficacy and safety of mechanical
prophylaxis, chemical prophylaxis or both for preventing VTE in
adolescents and adults undergoing elective spine surgery for
conditions other than trauma or malignant disease.2. Methods
We conducted a systematic review following the methodology
outlined in the Cochrane Handbook for Systematic Reviews of
Interventions.[19] We searched EMBASE and PubMed, from
inception toMarch 2018.Details of search strategy are provided in
Appendix 1, http://links.lww.com/MD/E224. We also manually
Medline (n=882) EMBASE (n=1569) 
Arcles 
2451 
Excluded following reading of 
tle and abstract (n=2276): 
– Duplicates 
– Did not meet selecon 
criteria 
Arcles (review 
of full text) 
175 
Included (n=35): 
– RCT (n=7) 
– Observaonal 
studies (n=28) 
Excluded following reading of full 
text (n=140) 
Medline (n=649) EMBASE (n=1569) 
Arcles 
2218 
Excluded following reading of 
tle and abstract (n=2070): 
– Duplicates 
– Did not meet selecon 
criteria 
Arcles (review 
of full text) 
175 
Included (n=35): 
– RCT (n=7) 
– Observaonal 
studies (n=28) 
Excluded following reading of full 
text (n=140) 
Figure 1. Flow chart showing eligibility of studies.
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Table 1
Summary of the studies of comparative effectiveness.
Chemical thromboprophylaxis
Du 2015 (RCT, n=665) Rivaroxaban vs Parnaparin DVT: 3 vs 5
PE: 1 vs 2
Bleeding: 21 vs 17
Voth 1992 (RCT, n=179) LMWH + dihydroergotamine vs sodium heparin + dihydroergotamine DVT: 4 vs 3
PE: 0 vs 0
Bleeding: 8 vs 7
Gruber 1984 (RCT, n=41) Miniheparindihydroergotamine + sodium heparin vs placebo DVT: 1 vs 0
PE: 0 vs 0
Bleeding: 6 vs 7
Mechanical thromboprophylaxis
Rokito 1996 (1) (RCT, n=110) CS vs CS + SPC DVT: 0 vs 0
PE: 0 vs 0
Bleeding: 0 vs 0
Wood 1997 (RCT, n=160) CS vs CS + SPC DVT: 1 vs 0
PE: 1 vs 0
Bleeding: 0 vs 0
Hamidi 2015 (RCT, n=82) CS vs CS + enoxaparin DVT: 2 vs 0
PE: 0 vs 1
Bleeding: 1 vs 0
Ferree 1993 (prospective, n=185) CS vs CS + SPC DVT: 4 vs 0
PE: 0 vs 0
Takahashi 2012 (retrospective, n=1975) No prophylaxis (1990–1996 period) vs foot pump + CS postoperatively
(2000–2011 period)
DVT: NR vs 0
PE: 8 (1.5%)vs 3 (0.2%)




Hamidi 2015 (RCT, n=82) CS vs CS + Enoxaparin See above (chemical)
Rokito 1996 (2) (RCT, n=110) CS vs CS + Coumadin DVT: 0 vs 0
PE: 0 vs 0
Bleeding: 0 vs 2
Nelson 1996 (RCT, n=117) CS + buffered aspirin vs CS + SPC + buffered aspirin DVT: 0 vs 0
PE: 0 vs 0
Cox 2014 (before-after, n=992) No standardized prophylaxis (2005–2007 period) vs protocolled use of
5000 IU heparin + SPC prophylaxis (2008–2010 period)
DVT: 25 vs 10 (P= .009)
PE: 6 vs 5
Bleeding: 6 vs 4
Nicol 2009 (before-after, n=1111) No prophylaxis (1985–1994 period) vs aspirin 150mg + SPC (1996–
2003 period)
DVT: 2 vs 1
PE: 0 vs 0
Yang 2015a (CCT, n=807) Mechanical prophylaxis (not specified) vs mechanical prophylaxis + LMWH
(4100UI/day)
DVT: 7 (8%) vs 97 (13.5%)
PE: 0 vs 0
Bleeding: 0 vs 2
Fawi 2017 (retrospective, n=2366 procedures) TED anti-embolic stockings vs TED anti-embolic stockings + subcutaneous
enoxaparin 40mg
DVT: 1 vs 0
PE: 9 (10%) vs 0
VTE: 10 vs 0 (P= .041)
Bleeding: 0 vs 0
Colomina et al. Medicine (2020) 99:21 Medicinechecked the reference lists of all relevant studies thatwere identified
by the abovementioned searches, aswell.Only studiespublishedas
a full report were included. In order to identify other potentially
relevant primary studies, we also reviewed the references of other
systematic reviews and clinical practice guidelines referring to
thromboprophylaxis in spinal surgery.
As inclusion criteria, we considered randomized controlled
trials (RCTs) and observational studies (minimum of 30
participants), whether controlled or not, that included adoles-
cent (>10 years old) and/or adult patients undergoing elective
surgery for deformities and/or degenerative spinal disease, from
C1 to S1. We excluded studies including other spinal4
conditions, if these represented >50% of the total study
population and specific data for the relevant population was
not available.
Studies had to evaluate, either alone or in combination, a
mechanical (CS or SPC), or chemical (low molecular weight
heparin [LMWH], low-dose unfractionated heparin [LDUH],
aspirin, or a new direct oral anticoagulants) thromboprophy-
laxis. Prophylaxis could be administered either pre, intra, and/or
postoperatively.We did not consider vena cava filter for purposes
of this systematic review. Outcomes of interest were DVT, PE,
and risk of bleeding or EDH. We excluded studies in language
other than English or Spanish.























































Figure 2. (A) Meta-analysis of incidence of DVT in Chemoprophylaxis studies. (B) Meta-analysis of incidence of PE in Chemoprophylaxis studies. (C) Meta-analysis
of incidence of bleeding in Chemoprophylaxis studies.
Colomina et al. Medicine (2020) 99:21 www.md-journal.comTwo authors (GU and BN) independently screened all articles
based on title and abstract. Disagreements were resolved through
discussion. Potentially relevant studies were obtained in full text,
and again, were independently assessed for inclusion by the
same two authors. A third author was contacted (MJC) when
disagreement persisted.
One author (KS or CR) extracted data from each study using a
predefined data extraction form, which included information
related to characteristics of the population, interventions and
definition of the outcome measures, details of design and results.
A second author (JPB or GU) cross-checked all the extracted data.
Two authors (KS or CR or JBP or GU) assessed the risk of bias of
included RCTs using the Cochrane Risk of Bias tool.[19]
For data analysis, we grouped studies into three categories:
chemoprophylaxis, mechanical, and mixed thromboprophylaxis.
We intended to compare the effectiveness between each category
using random-effects meta-analysis were possible. Otherwise,
results would be presented descriptively. As we anticipated to find
many single arm observational studies, we also planned to
combine incidence rates across studies for each category.3. Results
The initial search strategy retrieved 2451 unique references. After
the screening process, 35 studies met eligibility criteria, including 7
RCTs[11,20–25] and 28 observational studies[3,6,8,26–50] (Fig. 1). In
Appendix 2, http://links.lww.com/MD/E225 we provide details of5
the included studies. We also reviewed the references list from 8
systematic reviews,[5,12–14,51–54] and two clinical practice guide-
lines,[17,55] with no additional relevant primary studies identified.
Appendix 3, http://links.lww.com/MD/E226 provides a list of
excluded studies. Overall, most of the included RCTs showed an
unclear risk of selection bias, and a high risk of detection and
performance bias (Appendix 4, http://links.lww.com/MD/E227).
Regarding the observational studies, we considered that their
overall quality was low since either they used historical controls or
they were a single arm study, mostly retrospective. In addition,
there was great clinical variability in terms of study population,
type of surgery, methods of thromboprophylaxis, definition of
events, and/or VTE diagnostic methods among them.
Considering the high clinical heterogeneity among all the
included controlled studies, we decided not to perform a meta-
analysis of comparative effectiveness. Instead, we performed
a pooled analysis of the incidence rate of the events within each
group. We provide a narrative synthesis of the comparative
effects of different methods of thromboprophylaxis in Table 1.4. Effects on VTE and bleeding according to the
type of prophylaxis
4.1. Chemical prophylaxis (n=6)
Three RCTs and three single-arm observational studies were
included in this group. Two RCTs compared active pharmaco-
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Figure 3. (A) Meta-analysis of incidence of DVT in Mechanoprophylaxis studies. (B) Meta-analysis of incidence of PE in Mechanoprophylaxis studies. (C) Meta-
analysis of incidence of bleeding in Mechanoprophylaxis studies.
Colomina et al. Medicine (2020) 99:21 www.md-journal.comlogic prophylactic agents with each other (rivaroxaban vs
parnaparin, and LMWH+dihydroergotamine vs sodium heparin
+ dihydroergotamine),[20,23] while the other compared mini-
heparin dihydroergotamine + sodium heparin vs placebo,[25]
showing no significant differences between the groups for
thromboembolic events (DVT and PE) or for bleeding/EDH.
The three observational studies evaluated chemical prophylaxis
with dalteparin[3] or LMWH.[41,49]
The overall incidence (pooled effect across all chemoprophy-
laxis arms [n=8]) of DVT in these studies was 3.7% (0.0–13.1),
0.0% (0.0–0.0) for PE, and for bleeding complications 3.7%
(0.7–8.6) (Fig. 2A–C). In the study by Du et al[20] (rivaroxaban or
parnaparin groups) only 3 events out of 38 reported consisted of
serious bleeding events. In this study, there was also 1 case (0.3%)
of EDH in the rivaroxaban group and 1 death due to incoercible
gastrointestinal bleeding in the parnaparin group. Only one more
case of EDH was observed in the study by Yang et al,[49] which
implies an overall EDH rate of 0.10% (2 events in 2.062 patients)
in this group.
The meta-analysis showed high heterogeneity across studies
for DVT, due to a high incidence reported by Yang et al[49] of7
22.4% in contrast with all the rest of the studies, and
bleeding, where in the study by Gruber et al[25] 24% of the
patients in the chemoprophylaxis arm presented a bleeding
event defined as increased intraoperative bleeding, similar to
Voth et al[23] (overall rate was 8.4% for both study
groups).4.2. Mechanical prophylaxis (n=19)
Three RCTs and 16 observational studies (four of them
controlled) provided data for this group, including arms with
CS, CS+SPC, and foot pump during surgery+CS. Three out of
the seven controlled studies compared CS vs CS+SPC, with few
more VTE events in the CS alone group.[8,11,24] Twomore studies
compared CS vs CS+enoxaparin which found comparable[21] or
better[48] efficacy results with no increase in bleeding risk with the
use of enoxaparin. One more study compared no thrombopro-
phylaxis vs foot pump+CS with better results with the later.[38]
One more study compared mechanical prophylaxis (not speci-
fied) vs mixed,[43] with better results in favor of the mixed
thromboprophylaxis.


















































































































































Colomina et al. Medicine (2020) 99:21 MedicineTwelve single arm observational studies assessed a variety of
mechanical prophylaxis, including CS+SPC,[6,26,29,32,36,39]
SPC,[30,31] CS or SPC,[45] foot pump,[44] and mechanical (not
specified).[43]
The overall incidence (pooled effect across all mechanical
prophylaxis arms [n=23]) of DVT was 2.9% (1.2–5.2%) and
0.4% (0.1–0.8%) for PE. Bleeding complications had a 0.0%
incidence (Fig. 3A–C). Of note, only 10 studies accounting
for 12 study arms reported this last outcome with very few
events.
Similar to chemoprophylaxis, the meta-analysis showed high
heterogeneity across studies for DVT and moderate for PE. DVT
rates varied across studies between 0% in 5 study arms[8,11,24,38]
and 23.8% in Tominaga 2015,[39] or 22.6% in Yamasaki
2017.[39,45] As for PE, reported rates varied between 0% and 3%
in all studies, except for Piasecki 2008, that reported 7.6%
incidence.[44] As for bleeding, the estimates across studies were
consistent, and the overall risk was lower than that with
chemoprophylaxis.8
4.3. Mixed prophylaxis: chemical–mechanical (n=15)
Three RCT and 12 observational studies (five of them controlled)
provided data for this group. Two of the RCT compared mixed
with mechanical thromboprophylaxis[11,21] with similar results,
although in Rokito[11] mechanical prophylaxis proved to be safer
than mixed prophylaxis in terms of bleeding. Another RCT
compared two modes of same mixed thromboprophylaxis,[22]
with similar results. As for the controlled observational studies,
two studies compared mixed against no prophylaxis, with better
results for mixed thromboprophylaxis.[28,33] The other three
observational studies compared mixed vs mechanical thrombo-
prophylaxis,[43,46,48] with better results in favor of mixed
thromboprophylaxis. Overall, there was a slight increase in
bleeding risk in the mixed group.
The other seven single arm studies[27,34,35,37,42,47,50] evaluated
a variety of mixed interventions: nadroparin+CS,[42] LMWH+
CS,[27,35] warfarin or LMWH+CS+SPC,[34] LMWH+SPC,[37]
argatroban or LMWH+SPC,[50] and UH or LMWH or warfarin
+SPC.[47]






















































































Colomina et al. Medicine (2020) 99:21 www.md-journal.comThe overall incidence (pooled effect across all mixed
prophylaxis arms [n=14]) of DVT in these studies was 0.7%
(0.0–2.5), 0.1% (0.0–0.6) for PE, and for bleeding complications
0.2% (0.1–0.5) (Fig. 4A–C).
A high statistical heterogeneity was observed for DVT and PE
estimates across studies, and moderate for bleeding. Regarding
DVT, most of studies showed an incidence of <3%, except for
one study using LWMH+mechanical prophylaxis (not specified),
that showed an incidence of 13.5%.[43] As for PE, two single arm
studies (one comparing warfarin or LMWH+CS+SPC[34] and
the other comparing LMWH+SC [35]) and one study arm of a
RCT with enoxaparin+CS[21] showed higher rates compared to
the rest of studies.
The studies showed considerable clinical heterogeneity in the
populations included, types of surgery, and other important
factors related to potential bias.
Regarding EDH risk, the study by Gerlach et al[42] reported 13
(0.7%) cases of postoperative EDH. In 5 of them, the hematoma
occurred before nadoparin administration. Four patients with
EDH died (0.2%) and 4 others had a persistent neurological
deficit.
In the study by Cox et al,[28] 4 patients presented symptomatic
HED requiring surgical evacuation after implantation of a
thromboprophylaxis protocol with heparin.9
In the study by Al-Dujaili et al,[27] 3 cases of EDH occurred
(1.8%), all in patients who had received pharmacologic
prophylaxis. One patient required decompression surgery and
hematoma evacuation, with posterior recovery. None of them
had residual neurological deficits.
Other EDH events were observed in the study by Pateder
et al[34] (3 cases detected in patients receiving warfarin), Guo
et al[50] (1 case receiving LMWH), Schizas et al[35] (two cases of
postoperative hematomas, without development of neurological
symptoms or signs, requiring emergency evacuation), and Yang
et al[49] (two cases). Overall, the inside of EDH in this group was
of 0.30% (33 events in 10.933 patients).5. Discussion
Our results show that the mean incidence of DVT and PE is 3.7%
and 0%, respectively in the chemoprophylaxis group; 2.9% and
0.4% in the mechanoprophylaxis group; and 0.7% and 0.1% in
the mixed prophylaxis group. In the case of bleeding, the mean
incidence was 3.7%, 0%, and 0.2% for chemoprophylaxis,
mechanoprophylaxis, and mixed prophylaxis, respectively. We
were unable to obtain specific rates according to the type of
patient, type of surgery or spinal area, based on the available
data.

































































































Figure 4. (A) Meta-analysis of incidence of DVT in mixed prophylaxis studies. (B) Meta-analysis of incidence of PE in mixed prophylaxis studies. (C) Meta-analysis of
incidence of bleeding in mixed prophylaxis studies.
Colomina et al. Medicine (2020) 99:21 MedicineThe aim of this systematic review was to provide evidence for
clinicians seeking to establish optimum thromboprophylaxis for
the specific population of adolescent and adult patients
undergoing elective surgery of the spine. Contrary to other
reviews on this topic, we did not include studies or study arms
with patients who had not received any type of thrombopro-
phylaxis in our analysis. In our opinion, thromboprophylaxis is a
standard of care and the interest lies in determining which is best,
not in comparing thromboprophylaxis with no treatment.
Glotzbecker et al[5] published a systematic review including
elective, trauma and tumour surgery of the spine, where DVT
incidence was 4.6% for mechanical prophylaxis and 0.6 for
combined treatment, and PE incidence was 1.1% for mechanical
and 0.3% for combined prophylaxis. In our opinion, a major
limitation of this review is the inclusion of patients with different
diseases and a diversity of surgeries. This adds confusion to the
interpretation of the findings. Oliveira et al[13] conducted a
systematic using as search keywords “spine” and “thrombosis.”
They reported and overall rates of 3.55% and 1.04% for DVT
and PE, respectively, in all types of spine surgery. This review
presents obvious methodological flaws that seriously limit its
validity. Recently, Moshental et al[14] conducted a systematic
review and meta-analysis, whose aim was to determine the10incidence of DVT and PE in spine surgery (not including
pediatric, trauma nor neoplasic cases) in patients receiving no
thromboprophylaxis, mechanical prophylaxis, and chemical
prophylaxis. They found a higher incidence of these events in
the mechanical prophylaxis group (DVT: 1%, PE: 0.81%)
compared to the chemical prophylaxis group (DVT: 0.85%, PE:
0.58%) but the difference was not statistically significant. The
incidence of DVT/PE reported in this review is somewhat lower
than that reported in our study. As the authors recognize, this
may be explained by the fact that they only included symptomatic
DVT studies whereas in our review we included DVT diagnosed
with different techniques. In addition, our review included more
studies and, unlike Moshental et al, we excluded groups of
patients who did not receive any thromboprophylaxis. From the
point of view of safety, it does not currently seem appropriate to
provide any type of thromboembolic prophylaxis in this type of
surgery. In contrast to the study by Moshental et al,[14] which
contained a meta-analysis only of the incidence of complications,
our review also narratively describes the results of comparative
studies, and provides a more detailed description of each included
study.
Thromboprophylaxis in spine surgery is a standard of care but
evidence is lacking to prove which is the best method of


































































































Colomina et al. Medicine (2020) 99:21 www.md-journal.comtreatment. Since the first systematic review by Glotzbecker et al in
2009,[5] research on this topic has not been able to provide
relevant information to resolve this question. This opinion
coincides with the view set forth in the North American Spine
Society guidelines, which pointed out that evidence on the risks or
benefits of chemical prophylaxis for VTE in elective spine surgery
is insufficient to formulate recommendations.[17] In ACCP
9th edition (2012) guidelines,[18] within the recommendations
for patients undergoing spine surgery with no risk factors,
mechanical prophylaxis, preferably with SPC is recommended
over no prophylaxis (Grade 2C), unfractionated heparin (Grade
2C), or low-molecular-weight heparin (Grade 2C), without
specifying the spinal segment treated or the type of surgery. In
patients at a high risk for VTE undergoing spine surgery
(including those with malignant disease and those treated with a
combined anterior–posterior approach), the authors suggest
adding chemoprophylaxis medication to mechanical prophylaxis
once adequate hemostasis is established and the risk of bleeding
decreases (Grade 2C). In this guide, the need to use some kind of
thromboprophylaxis is clearly stated. In addition, the NICE
CG92 guidelines[56] followed this line, stating that patients
undergoing spine surgery should be evaluated on an individual
basis to weight the risk of bleeding against that of VTE because of11the considerable heterogeneity of this population as a risk group.
This document also mentioned that the appropriate time for the
start of postoperative anticoagulation and the type (mechanical
or chemical) has not yet been determined.
A peculiar feature of spine surgery is the risk of perioperative
bleeding and/or EDH. Many authors have taken a cautious
stance with regard to routine use of chemical prophylaxis in spine
surgery for conditions other than trauma and malignant
disease[48–52] because a larger incidence of postoperative bleeding
complications has been observed in relation to chemical
prophylaxis (3.7%) than combined prophylaxis (0.2%).[2] In
our review, the overall incidence of postoperative complications
related to surgical wound bleeding and postoperative blood loss
was 3.7% in chemoprophylaxis group, 0.0% in mechanical
group and 0.2% in mixed group. The incidence of EDH was
globally low; differences between the different types of
thromboprophylaxis were not striking (0.1 chemical, 0%
mechanical, and 0.3% combined). Our findings are overlapping
with those reported by other authors. Mosenthal et al[14] found
an EDH rate of 0.3% but no data on bleeding complications were
gathered. Cheng et al[12,14] conducted a systematic review
focused on the risk of anticoagulant administration in spine
surgery (mechanical thromboprophylaxis was not assessed). The




























































































Colomina et al. Medicine (2020) 99:21 Medicinerisk of major bleeding ranged from 0% to 4.3% with use of a
variety of anticoagulant agents. However, they could not
establish a clear relationship between the risk of bleeding and
the administered agent.
As a strength of our study, the search strategy included not only
databases but also a review of references of previous related SR.
Also, a detailed description of included primary studies, and a
meta-analysis of incidence of events for each type of thrombo-
prophylaxis. Among the limitations, 18 observational non-
controlled studies were included. The remaining 10 studies
included a control group, either randomized or not, but the
heterogeneous comparisons precluded to pool comparative data.
Some of the studies were old (publication range 1984–2018),
either retrospective and prospective. The inclusion criteria were
often poorly defined (population, interventions) and the
populations were heterogeneous. The baseline risk for VTE
and the timing of the prophylaxis and follow-up (at hospital
discharge, 1 week, 1 month) were not clearly specified in some
studies and were very diverse in others.
This systematic review confirms the low quality of research in
this field. However, some findings seem unquestionable. First,
there is a complete lack of information in the adolescent
population (under 18 years of age) on the incidence of VTE or PE
or the effectiveness of thromboprophylaxis in this age group.12Consequently, no recommendation is possible. Second, the use of
chemoprophylaxis is related to the occurrence of bleeding
complications. And third, there is no evidence of any clinically
relevant difference between chemoprophylaxis and mechano-
prophylaxis regarding VTE or PE incidence. This information
must be kept in mind by surgeons when deciding on the most
appropriate thromboprophylaxis for each patient. These data
would probably favor the use of mechanoprophylaxis in
uncomplicated, non-traumatic non-tumoral surgery, especially
when the procedure may require spinal canal opening.
Nonetheless, there is a need for additional, well-designed
comparative studies to establish high-level evidence for the
safety and effectiveness of this practice Appendix 5, http://links.
lww.com/MD/E228.Acknowledgments
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